--- SEARCH ---
WEATHER
CHINA
INTERNATIONAL
BUSINESS
CULTURE
GOVERNMENT
SCI-TECH
ENVIRONMENT
LIFE
PEOPLE
TRAVEL
THIS WEEK
Learning Chinese
Learn to Cook Chinese Dishes
Exchange Rates


Hot Links
China Development Gateway
Chinese Embassies

New Light Shed on Medicine
Chinese scientists have made significant headway in the development of new approaches to making a vast amount of "medically useless" microbes into a new source of medicine.

Cui Chengbin, a Ph.D and a researcher of pharmacology at Ocean University of Qingdao, East China's Shandong Province, declared at an international symposium last week that his team has succeeded in making some once-inactive microbes produce bioactive metabolites that may be used as a source of future medicines.

Their research, once successfully completed, may lead to a revolution in the pharmaceutical industry, experts said.

Microbes are very small living things that can only be seen under a microscope.

Cui did not name the microbes they've cultured, but said the experimental results were quite "encouraging" and proved their approaches applicable. "Present results suggest our research strategy is in the right direction and feasible, although some techniques are yet to be improved," he said in a keynote speech at the symposium on molecular science held by the university in Qingdao.

New medicines that have as a miraculous effect as that of penicillin may be developed using their new approaches in the long run, he predicted.

Derived from metabolites of a microbe called penicillium, penicillin was the first and probably the best-known drug produced with microbes and used to treat bacterial infections in humans.

Despite the great success of penicillin, the majority of microbes in the world remains away from human use.

The reason lies with the traditional processing techniques in extracting medically useful substances from microbes, according to Cui.

Ever since its discovery more than 70 years ago, penicillin, like many other antibiotics subsequently discovered, has remained little changed in terms of production techniques, most of which are based on the culture of penicillin-producing molds rather than chemical synthesis.

The making of penicillin, as well as its magical effect, has inspired scientists to look for other microbes that may function as biological medicine factories.

Yet it has been found that less than 5 percent of the microbes in the world are culturable like penicillium. But Cui believed that was too optimistic to be accurate.

"The real number, in my opinion, is less than 1 percent." he said. And even less can be developed as medicine, he added.

"A major parameter of their medical value is to see if the extracts from the microbes are bioactive against certain bacteria," Cui explained. "Unfortunately most of the extracts obtained by humans to date show no bioactivity and are therefore called useless microbes."

Cui believes they could be extremely valuable if new approaches are found to culture those non-culturable microbes and isolate and purify the bioactive substance from them.

Ribosome Engineering

One of his approaches is based on a newly emerging technology called "ribosome engineering," with which the scientists hope to transform the target microbe itself into a working machine against bacteria.

Ribosomes constitute one of the most essential components of the cell, the basic proposition of life. Ribosomes are important because they are tiny molecular machines responsible for translating the genetic code and synthesizing proteins. Thus, scientists also liken ribosomes to the miniature factories that build new proteins.

But recent studies found that it may serve more than just as a venue for protein synthesis; it "may also control genes dynamically by themselves," according to Kozo Ochi, the leading Japanese scientist who started ribosome engineering.

Cui and his colleagues noticed that altering certain parts of ribosomes can activate certain genes and awaken the potential functions of micro-organisms that lead to the production of new antibiotics and bioactive substances.

This process is generally known as "ribosome engineering."

In their experiment, some "useless microbes" were selected to undergo ribosome engineering and then were cultured, under the same conditions as that of the original strains.

Analysis of the cultured strains after their ribosomes were altered showed they contained bioactive substances in the metabolites, which proves the approach is feasible.

Cui disclosed that they have screened out several such microbial strains and are now engaged in the isolation of medically useful substances, a key step towards practically usable medicine.

"In fact, we've got the bioactive compounds," he disclosed.

But he denied any overnight success of a new magic medicine, saying many technical obstacles remain to be cleared.

For one thing, what they are doing is mainly focusing on basic research. Provided everything goes smoothly, it will take further clinical trials before a new medicine can be approved.

For another, ribosome engineering, as a newly emerging technology, is still immature.

The technology was initiated by a Japanese research team led by Kozo Ochi of the National Food Research Institute of Japan, who discovered in the late 1990s the novel gene-controlling functions of the ribosome.

Their discovery became precursor of a large-scale project started in 1998 in Japan called "Origin of Ribosome Engineering," for which Ochi serves as chief scientist.

The project with a five-year term, according to Ochi, is aimed at altering ribosomes in a controlled manner in order to produce desired microorganisms or proteins.

Cui got his inspiration from the project when he was a contract-researcher at the Institute of Physical and Chemical Research of Japan from 1994-97, a major participant of the project.

With the technology still under development, there remains uncertainties in its application in the field of medical research, Cui admitted.

Ribosome engineering is not the only approach Cui and his colleagues have adopted. Another approach Cui's team is now working on is like leasing a new machine to produce the desired substance.

Using genetic engineering technology, they extracted the genomic DNA from a non-culturable microbe and inserted it into a host microbe that is culturable but does not produce any bioactive substances.

Then the genetically engineered microbial strains were cultured and fermented under the same conditions as those of the host strains until sufficient microorganisms were produced for evaluation of their bioactivity.

Evaluation was also carried out to see if the inserted DNA of the target microbe has been working in the host microbe.

They have obtained several such engineered strains that produced bioactive substances and have isolated two bioactive compounds so far.

(China Daily July 26, 2002)

Chinese Medicine Favored by Germans
New Medicine Research Urged
Xinjiang Starts to Build 'Medicine Valley'
Biodiversity Breakdown May Threaten Chinese Medicine
Opportunities Open in China's Bio-medicine Industry: Expert
China's Pharmaceutical Industry Gets Major Push
WTO Brings Competition to China's Medicine Sector
Print This Page
|
Email This Page
About Us SiteMap Feedback
Copyright © China Internet Information Center. All Rights Reserved
E-mail: webmaster@china.org.cn Tel: 86-10-68326688
主站蜘蛛池模板: 黄色一级毛片免费| _妓院_一钑片_免看黄大片| 最新亚洲春色av无码专区| 亚洲精品免费观看| 粗大的内捧猛烈进出在线视频| 国产乱码精品一区二区三区中文| 亚洲综合精品香蕉久久网| 在线播放亚洲第一字幕| www国产无套内射com| 成年无码av片完整版| 久久亚洲精品无码aⅴ大香| 棉袜足j吐奶视频| 亚洲国产精品福利片在线观看 | 亚洲欧美日韩中文字幕在线一区 | 亚州免费一级毛片| 欧美国产日韩a在线视频| 亚洲狠狠婷婷综合久久久久| 猫咪免费人成网站地址| 再深点灬舒服了灬太大了乡村| 色综合久久综合中文小说 | 一本一本久久a久久精品综合| 日日夜夜操天天干| 久久久精品久久久久特色影视| 最近中文字幕免费4| 亚洲人成无码网www| 欧美成人免费观看久久| 亚洲护士毛茸茸| 欧美日韩亚洲无线码在线观看| 亚洲激情黄色小说| 求网址你懂你的2022| 亚洲综合色丁香婷婷六月图片| 琴帝type=小说| 你懂的在线视频网站| 福利片福利一区二区三区| 免费观看男人免费桶女人视频 | 一区二区三区高清在线| 性芭蕾k8经典| 一道本视频在线观看| 岛国片在线观看| www.精品视频| 天天躁夜夜躁狠狠躁2021|